#Antiemetic Drugs Market size

[credenceresearchdotblog]

The Gastrointestinal Agents Market is projected to grow from USD 59,863.47 million in 2023 to USD 92,867.89 million by 2032, reflecting a compound annual growth rate (CAGR) of 5.00%.The gastrointestinal (GI) agents market is a rapidly growing sector within the global pharmaceutical industry, driven by the increasing prevalence of gastrointestinal disorders, advancements in drug development, and rising awareness about digestive health. This article explores the key trends, market drivers, challenges, and future outlook of the gastrointestinal agents market.

Browse the full report at https://www.credenceresearch.com/report/gastrointestinal-agents-market

Overview of the Gastrointestinal Agents Market

Gastrointestinal agents are medications used to treat disorders of the digestive system, including conditions like gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), peptic ulcers, Crohn's disease, and ulcerative colitis. These agents are categorized into several classes, such as antacids, proton pump inhibitors (PPIs), H2 receptor antagonists, laxatives, antidiarrheals, and antiemetics. The global gastrointestinal agents market has witnessed significant growth due to the rising incidence of these disorders, coupled with lifestyle changes, aging populations, and increasing adoption of unhealthy diets.

Key Market Drivers

1. Rising Prevalence of Gastrointestinal Disorders: The increasing incidence of GI disorders is a major driver of the market. According to the World Gastroenterology Organization, gastrointestinal diseases affect millions of people worldwide, with a particularly high prevalence in developed countries due to sedentary lifestyles, poor diet, and high levels of stress.

2. Aging Population: The growing aging population is another critical factor contributing to market growth. Older adults are more susceptible to gastrointestinal issues due to age-related changes in the digestive system, making them a key demographic for GI agents.

3. Advancements in Drug Development: Ongoing research and development activities have led to the introduction of novel GI agents that offer improved efficacy and safety profiles. Biologics and targeted therapies, for example, are gaining traction in the treatment of inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis.

4. Increased Awareness and Diagnosis: Enhanced awareness about digestive health and the availability of advanced diagnostic tools have resulted in the early detection and treatment of GI disorders, further boosting the demand for gastrointestinal agents.

5. Rising Healthcare Expenditure: Increased healthcare spending, particularly in emerging economies, has improved access to healthcare services and medications, propelling the growth of the GI agents market.

Challenges Facing the Market

1. Side Effects and Safety Concerns: Many gastrointestinal agents, especially long-term treatments such as PPIs, have been associated with side effects like kidney issues, infections, and bone fractures. Safety concerns can lead to regulatory restrictions and affect market growth.

2. High Cost of Advanced Therapies: The cost of new biologics and targeted therapies can be prohibitive for patients and healthcare systems, particularly in low- and middle-income countries. This cost barrier may limit market expansion in some regions.

3. Generic Competition: The expiration of patents for several blockbuster drugs has led to the entry of generic versions, which, while increasing accessibility, have also intensified competition and put pressure on market prices.

Future Outlook and Opportunities

The gastrointestinal agents market is poised for continued growth, with several opportunities on the horizon:

1. Innovation in Drug Delivery Systems: Innovations in drug delivery systems, such as delayed-release formulations, are expected to enhance the effectiveness of GI agents and improve patient compliance.

2. Personalized Medicine: The development of personalized medicine approaches, where treatment is tailored based on genetic and environmental factors, is gaining momentum. This approach promises to optimize treatment outcomes for GI disorders, particularly IBD.

3. Expansion in Emerging Markets: Emerging markets, including Asia-Pacific and Latin America, offer significant growth opportunities due to improving healthcare infrastructure, increasing disposable incomes, and growing awareness about GI disorders.

4. Digital Health and Remote Monitoring: The integration of digital health technologies and remote monitoring solutions is expected to improve the management of chronic GI conditions, enabling better patient outcomes and driving the demand for GI agents.

Key Player Analysis

Johnson & Johnson

Pfizer Inc.

AstraZeneca

AbbVie Inc.

Takeda Pharmaceuticals

Bayer AG

GlaxoSmithKline plc.

Sanofi

Allergan

Boehringer Ingelheim

Segments:

Based on Type:

Dietary Supplements

Drugs

Antacids

Anti-diarrheal Agents

Anti-emetics

H2 Blockers

Laxatives

Proton Pump Inhibitors

Based on Disease Type:

Constipation

Diarrhoea

Gastroesophageal Reflux Disease

Inflammatory Bowel Disease

Peptic Ulcer Disease

Based on Route of Administration:

Oral

Parenteral

Rectal

Based on End-User:

Homecare

Hospitals & Clinics

Based on Distribution Channel:

Offline Pharmacies

Online Pharmacies

 Based on the Geography:

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/gastrointestinal-agents-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[delveinsight12]

Urea Cycle Disorders Market Growth Anticipated by 2032 | Major Players: Aeglea BioTherapeutics, Immedica Pharma, Ultragenyx Pharmaceutical, Arcturus Therapeutics, expected to boost the market

In the market landscape of Urea Cycle Disorders, an impressive surge is expected during the study period spanning 2019 to 2032, according to the latest report titled  “Urea Cycle Disorders Market Insights, Epidemiology and Market Forecast 2032” from DelveInsight. 

The Urea Cycle Disorders market report sheds light on Urea Cycle Disorders current treatment practices, upcoming drugs in the Urea Cycle Disorders pipeline, market shares of individual therapies, and the anticipated trajectory of the Urea Cycle Disorders market size from 2019 to 2032 across the 7MM (the United States, the EU-4 comprising Italy, Spain, France, and Germany, the United Kingdom, and Japan).

Driving Forces Behind the Urea Cycle Disorders Market Growth

The market size shall grow during the forecast period, i.e., 2023–2032 owing to the increasing prevalence of Urea Cycle Disorders. The market size is expected to increase during the study period.

Discover the Anticipated Evolution and Growth of the Market @ Urea Cycle Disorders Therapeutics Market Forecast

Therapeutic Advancements and Emerging Treatments:

Urea Cycle Disorders Clinical Trial Progression: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2032. Pioneering companies, including Aeglea BioTherapeutics, Immedica Pharma, Ultragenyx Pharmaceutical, Arcturus Therapeutics, and others, are actively engaged in developing novel drugs for potential market entry.

Urea Cycle Disorders Innovative Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Urea Cycle Disorders. Therapies such as LOARGYS (pegzilarginase), DTX301, LUNAR-OTC (ARCT-810), and others are driving the Urea Cycle Disorders market.

Urea Cycle Disorders Treatment Market

The treatment of disorders related to the urea cycle is a lifelong process aimed at managing symptoms and doesn't cure the disorder. Strategies include monitoring ammonia levels using blood tests (serum and plasma levels) at regular intervals and using the results to optimize treatment methods. In the current market scenario, recommended therapies to possibly slow the progression of the disease include sodium benzoate, sodium phenylacetate, Glycerol phenylbutyrate, sodium phenylbutyrate, and antiemetic agents. 

These drugs lower blood ammonia concentrations by conjugation reactions involving acylation of amino acids. For neonates with hyperammonemia, the immediate treatment goal is a rapid lowering of ammonia and reducing dietary protein intake. Hemodialysis is very effective at reducing plasma ammonia and should immediately be initiated if elevated hyperammonemia is observed. Ammonia scavenger medications such as AMMONUL IV are also useful. AMMONUL IV acts by removing glycine and glutamate from plasma thereby their reducing contribution to ammonia formation.

Urea Cycle Disorders Treatment Market

The dynamics of the Urea Cycle Disorders market are expected to change owing to a robust pipeline products. Some of the key players involved in the development of novel drugs are Aeglea BioTherapeutics, Immedica Pharma, Ultragenyx Pharmaceutical, Arcturus Therapeutics, and others.

LOARGYS (pegzilarginase) is an engineered human arginase I enzyme designed to degrade the amino acid arginine. Pegzilarginase is being developed to treat two extremes of arginine metabolism, including arginine excess in patients with Arginase 1 Deficiency, as well as some cancers which have been shown to have a metabolic dependency on arginine. The company has completed a Phase III clinical study which demonstrated reduction in blood arginine levels in patients with ARG1-D. The therapy was well tolerated among the patients. Recently, in October 2023, Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending marketing authorization of LOARGYS (pegzilarginase) for the treatment of arginase 1 deficiency (ARG1-D) in patients two years and older. 

DTX301 is an investigational gene therapy being developed for the treatment of individuals with ornithine transcarbamylase (OTC) deficiency which is the most common urea cycle disorder. DTX301 is designed by Ultragenyx Pharmaceutical to deliver OTC gene expression in a durable fashion, with the goal of preventing or reducing the occurrence of complications associated with OTC deficiency. It has been granted Orphan Drug Designation in the United States, EU and United Kingdom and Fast Track Designation in the United States. Long term Phase I/II data demonstrated an acceptable safety profile and durable metabolic control and sustained responses. The company is conducting a Phase III (NCT05345171) trial to evaluate the efficacy of DTX301 on the improvement of ornithine transcarbamylase (OTC) function by maintaining safe plasma ammonia levels with removal of dietary protein restriction and alternative pathway medication.

LUNAR-OTC (ARCT-810) is messenger RNA (mRNA) coding for Ornithine Transcarbamylase (OTC) formulated in a lipid nanoparticle (LNP). Arcturus Therapeutics is developing mRNA medicines that enable OTC patients to make healthy functional OTC enzyme in the liver cells. The early phase studies demonstrated efficacy of the therapy in restoration of the urea cycle function to normal levels and increased survival. Currently, ARCT-810 is being investigated in Phase II (NCT05526066) clinical development to evaluate the safety, tolerability and pharmacokinetics of ARCT-810 in adolescent and adult participants with ornithine transcarbamylase deficiency.

Leading Urea Cycle Disorders Companies and Emerging Drugs: Pioneering companies such as Aeglea BioTherapeutics, Immedica Pharma, Ultragenyx Pharmaceutical, Arcturus Therapeutics, among others, are actively developing novel drugs for potential entry into the Urea Cycle Disorders market.

Urea Cycle Disorders Therapeutic Landscape: Key therapies identified for Urea Cycle Disorders treatment include LOARGYS (pegzilarginase), DTX301, LUNAR-OTC (ARCT-810), and more.

Urea Cycle Disorders Overview:

Urea cycle disorders (UCDs) are a group of rare genetic disorders that affect the body's ability to eliminate ammonia, a waste product formed during the breakdown of proteins. Normally, ammonia is converted into urea in the liver through a series of biochemical reactions known as the urea cycle. Urea is then excreted from the body through urine.

In individuals with urea cycle disorders, one of the enzymes involved in the urea cycle is deficient or dysfunctional, leading to the accumulation of ammonia in the blood. This elevated ammonia, known as hyperammonemia, can be toxic to the brain and nervous system, causing neurological damage and potentially life-threatening complications.

There are several types of urea cycle disorders, each caused by mutations in specific genes that encode enzymes critical to the urea cycle. These disorders include:

Ornithine Transcarbamylase (OTC) Deficiency: This is the most common urea cycle disorder, caused by a deficiency in the OTC enzyme. It is an X-linked disorder, primarily affecting males. Symptoms can range from mild to severe and may appear shortly after birth or later in life.

Carbamoyl Phosphate Synthetase (CPS) Deficiency: CPS deficiency is a rare autosomal recessive disorder caused by mutations in the CPS1 gene, leading to reduced or absent activity of the CPS enzyme. Symptoms can be severe and appear soon after birth.

Argininosuccinic Acid Synthetase (AS) Deficiency: AS deficiency results from mutations in the ASS1 gene, leading to decreased production of the AS enzyme. Symptoms can range from mild to severe and may present at different ages, from infancy to adulthood.

Arginase Deficiency: This disorder is caused by mutations in the ARG1 gene, resulting in a deficiency of the arginase enzyme. Symptoms often appear in early childhood and can vary in severity.

Symptoms of urea cycle disorders can include vomiting, lethargy, irritability, seizures, developmental delay, coma, and even death if not promptly treated. Diagnosis involves blood tests to measure ammonia levels and specific metabolites related to the urea cycle, as well as genetic testing to identify the specific enzyme deficiency.

Treatment aims to reduce ammonia levels and prevent its accumulation. This often involves dietary restrictions, medications like ammonia-scavenging drugs, and in severe cases, dialysis to remove excess ammonia from the blood. Long-term management by metabolic specialists and genetic counselors is essential for individuals with urea cycle disorders. Early detection and intervention are critical to minimize the risk of neurological damage and improve outcomes for affected individuals.

Key Facts Urea Cycle Disorders Market Report:

Key players such as Aeglea BioTherapeutics, Immedica Pharma, Ultragenyx Pharmaceutical, Arcturus Therapeutics, and others are investigating its candidates for Urea Cycle Disorders.

Urea Cycle Disorders pipeline includes the major therapies such as LOARGYS (pegzilarginase), DTX301, LUNAR-OTC (ARCT-810), and others. 

In December 2022, the US FDA approved OLPRUVA (sodium phenylbutyrate) to treat certain patients living with urea cycle disorders (UCDs). Acer Therapeutics presented data from a survey designed to quantify preferences of healthcare providers for Urea Cycle Disorders (UCDs) at the 44th Annual Meeting of the Society for Inherited Metabolic Disorders (SIMD) on March 18th to 21st.

Urea Cycle Disorders Epidemiology Segmentation:

According to NORD, OTC deficiency affects males more often than females and most males are symptomatic in nature. In males, symptoms typically begin during the first few days of life.

According to reports published by the Centers for Disease Control and Prevention (2022), the anticipated incidence of UCD is 1 in 8,500 births. The research findings suggest that many of the cases of UCD persist undiagnosed. In some of the cases, the newborn with UCD dies without a conclusive diagnosis.

According to the American Association for Clinical Chemistry (2019), the incidence of Urea Cycle Disorders, or UCDs, in the US is estimated to be around 1 in 8,200 births. The mortality rate is 24% in neonatal cases, and 11% in later onset cases.

For in-depth insights, access the full report @ Urea Cycle Disorders Market Outlook 2032

[infinitiresearch]

Antiemetic Drug Market| Market Size, Trends, Analysis, Growth and Forecast, 2023 – 2027

Originally published on Technavio: Antiemetic Drug Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast 2023-2027

Analyzing the antiemetic drug market across regions including North America, Europe, Asia, and the Rest of the World (ROW) provides insights into significant growth opportunities. In North America, particularly in the United States, the market is expected to witness robust growth due to factors such as the high prevalence of chemotherapy-induced nausea and vomiting (CINV) among cancer patients, increasing adoption of antiemetic drugs for postoperative nausea and vomiting (PONV), and the presence of well-established healthcare infrastructure. Additionally, the growing geriatric population, which is more prone to nausea and vomiting, further contributes to market expansion.

Similarly, in Europe, countries like Germany and the UK are key markets for antiemetic drugs. The region benefits from a strong healthcare system and high awareness about the availability of antiemetic treatments. The increasing prevalence of cancer and chemotherapy procedures, coupled with rising awareness about the management of chemotherapy-related side effects, drives market growth in these countries. Additionally, advancements in antiemetic drug formulations and the introduction of novel therapies contribute to market expansion.

In Asia, countries like China and Japan are witnessing significant growth in the antiemetic drug market. Factors such as the rising incidence of cancer, increasing healthcare expenditure, and expanding access to healthcare services drive market growth in the region. Moreover, the adoption of Western lifestyles and dietary habits leading to gastrointestinal disorders and the growing elderly population contribute to the demand for antiemetic drugs. Additionally, government initiatives to improve healthcare infrastructure and access to essential medicines further support market growth in Asia.

The Rest of the World (ROW) region presents opportunities for market players to expand their presence. Countries in Latin America, the Middle East, and Africa are witnessing increasing incidence rates of cancer and other diseases associated with nausea and vomiting. The growing recognition of the importance of managing these symptoms effectively, coupled with efforts to improve healthcare infrastructure and access to essential medicines, drives market growth in these regions.

To Learn deeper into this report , View Sample PDF

Overall, the antiemetic drug market is poised for significant growth across regions, driven by factors such as the increasing prevalence of cancer and chemotherapy procedures, rising awareness about the management of chemotherapy-related side effects, and improvements in healthcare infrastructure. Key markets such as the US, Germany, UK, China, and Japan are expected to lead the way in terms of market size and adoption rate, while emerging markets in Asia and the Rest of the World present untapped opportunities for market expansion.

For more information please contact.

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: media@technavio.com

Website: www.technavio.com/

[westcoastmeds]

From Buds to Business: Understanding Michigan's Cannabis Economy

Due to legislation and practical reasons, 24-hour dispensaries in Michigan can be difficult to establish. Marijuana, often known as cannabis, has a complicated history that stems from its numerous applications and contentious position. While the plant's recreational use is well recognised, its therapeutic qualities have attracted growing attention in recent years. 

Cannabis Best Dispensary Deals in Detroit Marijuana is derived from the Cannabis plant, which is made up of various species, the most known of which are Cannabis sativa and Cannabis indica. Over 100 different substances known as cannabinoids are produced by the plant, each with distinct effects on the human body.

Dispo Near me, marijuana's psychotropic component is known for its analgesic qualities. Medical cannabis is frequently given to treat chronic pain caused by illnesses such as arthritis, multiple sclerosis, and migraines.

west cost meds closest dispensary  to me in michigan Medical marijuana has been shown to be effective in lowering nausea and vomiting, particularly in chemotherapy patients. THC and CBD both contribute to antiemetic effects, which provide respite to cancer patients.

Pot dispensaries in Michigan are businesses that are legally permitted to sell medical and recreational marijuana. These dispensaries nearby, which are controlled by the Marijuana Regulatory Agency, offer a variety of cannabis options to qualifying consumers, as well as a legal channel for the purchase of marijuana and related products for medicinal or adult-use purposes.

The best priced dispensary in Michigan can be determined by a variety of criteria, including personal tastes, geography, and the precise goods you're looking for detroit dispensary deals may also differ depending on whether the dispensary serves the medical or recreational markets.

A weed dispensary  Detroit, Michigan, is a business that is legally permitted to sell marijuana and cannabis products. These dispensaries follow Michigan Marijuana Regulatory Agency (MRA) laws and serve both medicinal marijuana patients and adult-use (recreational) consumers.

When buying edibles weed in Detroit****, it's important to think about the dosage and start with a small amount, especially if you're new to cannabis edibles. When compared to smoking, the onset of effects can be slower, so it's crucial to be patient and careful of the appropriate serving amount.

Edible weed candy is cannabis-infused confectionery that contains cannabinoids like THC or CBD. These sweets, which come in a variety of forms, flavours, and sizes, are a popular type of edible cannabis product.

vape pens In Detroit, are handheld devices used to vaporise cannabis extracts or e-liquids. These devices are made up of a battery, a heating element, and a chamber that holds the cannabis extract or vape juice. Vape pens have grown in popularity as a discreet and simple way of cannabis consumption. The best vape cartridge in Michigan, or any other place, is subjective and depends on personal preferences, such as desired effects, flavour profiles, and potency.

Cannabis concentrates in Detroit, like elsewhere, refer to goods extracted and concentrated from the cannabis plant to create a strong drug rich in cannabinoids. Wax or Budder: A soft, flaky substance that resembles wax or butter in texture. Shatter: A brittle, glass-like concentration that, when handled, can "shatter" into fragments.

These concentrates weed  in Detroit are made using a variety of extraction procedures that separate and concentrate the plant's cannabinoids and terpenes. Concentrates are known for their potency, providing a more intense experience than standard cannabis flower.

[rohans18]

Antiemetics Market Applications and Current Status

Global Antiemetics Market, By Drug Class (5-HT3 Receptor Antagonists, Dopamine Antagonists, NK1 Receptor Antagonist, Antihistamines (H1 histamine receptor antagonists), Cannabinoids, Benzodiazepines, Anticholinergics, Steroids, Others), Application (Chemotherapy, Motion Sickness, Gastroenteritis, General Anesthetics, Opioid Analgesics, Dizziness, Pregnancy, Food Poisoning, Emotional Stress, Other), End-User (Hospitals, Clinics, Pharmacies, Online Pharmacies), Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028

In the consistent Antiemetics market research report, industry trends are put together on macro level with which clients can figure out market landscape and possible future issues about Antiemetics industry. The scope of this market report include but is not limited to latest trends, market segmentation, new market entry, industry forecasting, future directions, opportunity identification, strategic analysis and planning, target market analysis, insights and innovation. The report presents with the CAGR value fluctuations for the specific forecasted period which helps decide costing and investment strategies. An influential Antiemetics market report brings precise and exact market research information that drives business into the right direction.

Key Players

GSK Plc. (U.K.)

Galderma (Switzerland)

Valeant Pharmaceuticals (Canada)

Hisamitsu Pharmaceuticals Co. Inc. (Japan)

Cipla Inc. (India)

Glenmark (India)

Johnson & Johnson Private Limited (U.S.)

Novartis AG (Germany)

Bayer AG (Germany)

Crescita Therapeutics Inc. (Canada)

Biofarmitalia S.R.L (Italy)

Browse More Info @ https://www.databridgemarketresearch.com/reports/global-antiemetics-market

The research studies entailed in the winning Antiemetics market report supports to estimate several important aspects that includes but are not limited to investment in a rising market, success of a new product, and expansion of market share. The strategies underlined here mainly consist of new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others that boost footprints in this market. Several other factors such as import, export, gross margin, price, cost, and consumption are also analyzed under the section of production, supply, sales and market status.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Antiemetics Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:  Global Market

Part 04: Global Market Size

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 More Reports:

Diuretic Drugs Market

Patient Engagement Technology Market

Healthcare Business Intelligence Market

Chinese Hamster Ovary cells (CHO) Market

Anti-cancer Drug Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

[danielcraigazot]

Global Acute Migraine Drugs Market Trends, Analysis, Segmentation, Forecast to 2028

Azoth Analytics has released a research named “Acute Migraine Drugs Market (2023 Edition)” which provides a complete analysis of the Global Acute Migraine Drugs industry in terms of market segmentation by Drugs type, Route Administration, Availability, and region.

The research also looks at the market's growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market's evolution.

During the forecast period, 2023-2028, the global Acute Migraine Drugs market is expected to expand at a CAGR of 7.82%. Migraines are a common neurological disorder, affecting approximately 1 in 7 people worldwide. As the prevalence of migraines continues to grow, so too makes the demand for effective treatments. Migraine is a complex neurological disorder that is ranked by the World Health Organization as the seventh most disabling condition in the world, and the fourth among women. Acute Migraine medications are designed to relieve a migraine attack. It's typically best to start taking them as soon as the symptoms occur. While many migraine sufferers take over-the-counter NSAIDs like ibuprofen, Triptans are frequently recommended for acute migraine relief.

The Global Acute Migraine Drugs Market is expected to generate USD 14 billion by the end of 2028, up from USD 8.40 billion in 2021. The global market for acute migraine medications is expected to grow due to an increase in the disorder's prevalence as well as increased demand for abortive therapies due to their high efficiency and targeted drug release. Nonetheless, Migraine pharmacologic treatment is frequently tailored to the patient's specific migraine symptoms. For example, the presence of nausea necessitates the use of nasal or parenteral routes of delivery as well as antiemetic medicines.

Migraine is becoming more common among teenagers and adults aged 20 to 45. These age groups usually seek treatment from healthcare professionals sooner due to high medical awareness among them, which supports the growth of the Acute Migraine Drugs Market. Migraine has a significant economic impact on the workplace since 90% of individuals are unable to work during a migraine episode. Migraines are estimated to cost a business between USD 84,000 and 181,000 thousand for every 1,000 employees.

Improved awareness and diagnosis of migraines have led to an increased demand for effective treatment options. Also, advances in drug development have led to the development of new drugs that are more effective and have fewer side effects than previous treatments.

Furthermore, with the rise of precision medicine, there is a growing demand for personalized treatment options for migraine sufferers. As healthcare expenditure continues to rise, more funding is being allocated toward the development and marketing of new acute migraine drugs.

The research is global in nature and covers a detailed analysis of the market in America (U.S., Canada, Mexico, Rest of Americas), Europe (Germany, U.K, France, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Rest of Asia-Pacific), and Middle East and Africa. Additionally, the research report displays data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities, demand for future forecast, and so on.

New drugs are being developed to target specific neurotransmitters and receptors involved in migraine pathophysiology. These drugs may offer improved efficacy and fewer side effects compared to traditional medications.

Drug delivery systems such as intranasal sprays and injectable formulations are being developed to improve the bioavailability of acute migraine drugs and enhance patient compliance. Combination therapies are being developed to target multiple pathways involved in migraine pathophysiology. These therapies have the potential to be more effective than single-target drugs. Advancements in precision medicine have led to the development of personalized treatment options for migraine sufferers. Genetic testing and biomarker analysis can help identify patients who are most likely to benefit from specific drugs that are fueling the market.

This study also contains company profiling and the current competition status of some of the leading players in the Global Acute Migraine Drugs Market of Eli Lilly and Company, GSK plc., Bayer AG, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Novartis, Merck & Co., Inc., Pfizer Inc., Boehringer Ingelheim, and others. The company profiling includes critical information such as a business overview, products and services, key financials, and recent events and developments. Overall, the report provides a detailed overview of the Global Acute Migraine Drugs Market, which will assist industry consultants, equipment manufacturers, existing players looking for expansion opportunities, new players looking for opportunities, and other stakeholders in aligning their market-centric strategies with current and expected future trends.

[marketinsightshare]

Antiemetic Drugs Market - Forecast(2022 - 2027)

Antiemetic Drugs Market size is estimated to reach $6.1 billion by 2027, growing at a CAGR of 5.3% during the forecast period 2022-2027. Antiemetic drugs fall under the category of therapeutic drugs which are taken into account to treat uncontrollable reflexes like nausea and vomiting. This uneasiness or sudden urge to eject the content of the stomach is often triggered by vestibular illnesses, digestion problems, pregnancy, and acts as an emetogenic chemotherapeutic agent. Dopamine receptors, histaminergic receptors, and various antagonists are used as first-line treatments to cure the urge to vomit. With advancements in mediums of transportation and connectivity many people nowadays are prone to motion sickness. While traveling it becomes hard for the brain to figure out whether the body is moving or motionless because various motion-sensing parts confuse it by sending contradictory signals. The outlook for the antiemetic drugs market is remarkably captivating with growing cancer complications worldwide. Heightened mobility of people with escalating per capita income, proliferation in cancer complications are factors set to drive the growth of the Antiemetic Drugs Market for the period 2022-2027.

Report Coverage

The report: “Antiemetic Drugs Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Antiemetic Drugs Market.

By Type: Cannabinoids, Serotonin and Dopamine antagonists, NK1 receptor antagonist, Benzodiazepines, 5-HT3 receptor, Anticholinergic, Steroid-corticosteroids, and others. By Application: Migraine, Anesthesia, Vestibular illnesses, Pregnancy, Chemotherapy, Opioid analgesics, Palliative care, Gastroenteritis, Opioid-induced nausea. By Distribution Channel: Offline and Online platforms. By Geography: North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, and Rest of South America) and Rest of World (the Middle East and Africa).

Key Takeaways

Geographically, the North America Antiemetic Drugs Market accounted for the highest revenue share in 2021. It is owing to the vast array of population receiving chemotherapy treatments which in turn enforces people to start on medications related to antiemetics. However, Asia-pacific is expected to offer lucrative growth opportunities to the marketers in the projected period of 2022-2027 owing to a substantial shift of government’s focus to enhance the medicinal reach and pro-active budget allocation.

Enlarging research activities for novel drug discovery is said to be a preeminent driver driving the growth of the Antiemetic Drugs Market. Side-effects connected with the overuse of antiemetic drugs are said to reduce the market growth.

Detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Antiemetic Drugs Market report.

Antiemetic Drugs Market- Geography (%) for 2021.

For More Details on This Report - Request for Sample

Antiemetic Drugs Market Segment Analysis-By Application

The Antiemetic Drugs Market based on the application type can be further segmented into migraine, anesthesia, vestibular illnesses (=motion sickness), pregnancy, chemotherapy, opioid analgesics, palliative care, gastroenteritis, opioid-induced nausea. The chemotherapy and pregnancy-induced nausea and vomiting held the largest segment in 2021. The growth in cancer treatment procedures like chemotherapy is owing to the heightened number of cancer patients worldwide. Bad ingestion habits, excess use of alcohol and smoking, worsening pollution situations are some common reasons behind soaring cancer cases. Furthermore, nausea and vomiting are very common during pregnancies which have made usage of antiemetic drugs a norm. The vestibular illnesses and chemo-induced vomiting segment is estimated to be the fastest-growing segment with a CAGR of 5.9% over the forecast period 2022-2027. This growth is owing to the mounting usage of antiemetic drugs during traveling and chemotherapies. Cardiovascular diseases are the leading cause of death around the globe. Around 30-32% of demises worldwide occur due to cancer and heart attacks. Considering the vulnerable immunity, the number is anticipated to rise in foreseeable future.

Antiemetic Drugs Market Segment Analysis-By Distribution Channel

The Antiemetic Drugs Market based on distribution channels can be further segmented into hospital pharmacies, retail pharmacies, drug stores, and others. The hospital segment held the largest share in 2021. The growth is owing to the upsurging number of pregnancy treatments and cancer-associated treatments like chemotherapy. With rapid modernization, a huge shift in attitudes of people from treatments to prevention can be witnessed. Therefore, broadening health awareness among people encourages them to undergo all necessary procedures well in advance. Moreover, the refining infrastructure of hospitals and other medical facilities is contributing factor in the growth of the antiemetic drugs market. There are around 71 NCI designated Cancer hospitals within the 36 states and District of Columbia, which further eases the use of drugs pertaining to nausea. However, the retail pharmacies segment is estimated to be the fastest-growing segment with a CAGR of 6.2% over the forecast period 2022-2027. This growth is owing to the across-the-board presence of retail pharmacies in urban as well as rural areas. On another hand, augmenting the application of antiemetic drugs in the treatment of motion sickness encourages people to buy such medication over-the-counter without any prior prescription from doctors.

Antiemetic Drugs Market Segment Analysis-By Geography

The Antiemetic Drugs Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the largest share with 34% of the overall market in 2021. The growth in this segment is owing to the factors such as the higher prevalence of breast and lung cancer cases among the American population. Attributing to full-fledged economies North-American people enjoy a high standard of living. Additionally, they have access to the world’s best healthcare facilities such as hospitals and diagnostic laboratories which is a prominent factor fueling the growth in the respective segment. Nevertheless, the Asia-Pacific is expected to be the fastest-growing segment over the forecast period 2022-2027. This growth is owing to shooting up cancer prevalence due to the broadening geriatric population, enlarging affluence of Asian nations. As per capita income of Asian states is augmenting people are buying their personal vehicles which are resulting in expansion of traveling trips. The poor quality and unhygienic buses and trains in the nations like India is another factor that stimulated the urge because for impoverished and middle-class sections the public transportation is the most common way of commuting from one place to other. India saw a 137% increase in its healthcare budget allocation which would prove out to help those who need it the most, especially the underprivileged cancer patients requiring chemotherapy.

Antiemetic Drugs Market Drivers

The proliferating pervasiveness of cancer is Anticipated to Boost Product Demand

Following heart-attack cancer is the second biggest cause stimulating the death figures throughout the globe. Every year around 9-10 million people lose their life to it. Breast and lung cancer are the two main categories as their prevalence has augmented on an unprecedented scale. With 2.3 million diagnosed cases in 2020, breast cancer claimed the lives of more than 680,000 people worldwide. Similarly, with the escalating smoking trend, the pervasiveness of lung cancer is growing. According to a study, 82% of lung cancer complications are caused by smoking. On another hand, accruing the old-age population is another prominent factor in the growth of the antiemetic drugs market.

Accruing per capita income is Expected to Boost Product Demand

Rapid modernization and industrialization around the globe are fueling the per capita income of countries. If we compare the last two decades The unemployment rates have reduced as people today have more means to earn a living as compared to earlier times. The trends of buying personal vehicles, exploring the world, and visiting amusement parks have multiplied in recent years which is a prominent factor in the growth of the respective market. More than 17% of the world population has their own cars and the number is expected to accrue in upcoming years as purchasing power is expanding. Many European country’s per capita has crossed the $65000 mark. Besides, the living standard in the so-called third world is improving. People are traveling more than ever with the availability of adequate transportation. All these aforementioned factors are prompting the use of antiemetic drugs.

Antiemetic Drugs Market Challenges

Health hitches associated with overuse of antiemetic drugs are Anticipated to Hamper Market Growth

There are several adverse side effects accompanied by the use of antiemetic drugs which are anticipated to cripple the growth of the antiemetic market. These effects can be life-threatening in a few cases. Anticholinergic effects which include tachycardia, constipation, hallucinations, schizophrenia are connected with the use of dopamine antagonists. Furthermore, antiemetic drugs including serotonin antagonists, benzodiazepines, and cannabinoids may lead to several other health hitches like QT prolongation, extrapyramidal symptoms (=akathisia, dystonia, and parkinsonism), sedition.

Antiemetic Drugs Market Competitive Landscape:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Antiemetic Drugs Market. The Top-10 Key companies of Antiemetic Drugs Market are-

Abbott

Sanofi-Aventis

GlaxoSmithKline

F. Hoffmann-La Roche

Merck & Co.

Novartis AG

Baxter International

Eisai Co.

Daiichi Sankyo

Eli Lily and Company

Recent Developments/Product Launches:

On November 9, 2021, “Sanofi”, a healthcare company based in Paris, France announced the acquisition of “Kadmon Corporation.” Kadmon is a US-based biopharma company that develops various therapies. Sanofi wrapped up the acquisition process with a payment of $1.9 billion. The existing shareholders are going to get $9.50 per share. Additionally, Sanofi’s price tag has been representing a 79% premium over the Kadmom close price of $5.30. Further, Sanofi has been under pressure owing to its slow drug pipeline presence.

On July 14, 2021, Indiana, United States-based pharmaceutical company “Eli Lilly and Company” announced the successful acquisition of biotechnology firm “Protomer technologies.” Protomer is famous for its advanced protein therapy production. The company's proprietary chemical biology-based platform enables the development of therapeutic peptides and proteins with a tunable activity that can be controlled using small molecules. Moreover, the transaction is brought to an end with a payment of $1 billion.

On March 15, 2021, a Switzerland-based multinational health firm “F. Hoffman-la Roche” announced that it has reached an agreement with GenMark Diagnostics, a company that provides diagnostic solutions and is headquartered in California, United States. Roche paid $1.8 billion in order to bring the deal to an end. Moreover, every existing shareholder of GenMark will receive $24.05 per share.

[doyothirdpartymunuifacture]

Their Party manufacturing Company in India- DOYO

A third-party manufacturing company in India - DOYO, the leading third-party Pharma manufacturing company - is ISO certified and has 25+ different products. Segment manufacturing while all manufacturing plants are WHO and GMP certified. Becoming a certified third-party manufacturing company in India. We have one-stop solutions that include leadership and consultation on pharma marketing, unique and innovative packaging, and packaging content concepts to meet all needs. We provide clinical trials and lab tastes as well as quality assurance for the entire product.

 DOYO is a leading third-party manufacturing company in India offering tablets, capsules, powders, injectors, and oral solutions such as high-shear granulation, B-layers, liquid-bed processing, and film coatings. If you are looking for manufacturers who are involved in integrated manufacturing then join us. We are also developing products on customization.

Strenuously Growth of the Pharmaceutical Industry:-

The pharmaceutical industry is growing at a growth rate of over 20% CAGR. The fast-growing Indian pharmaceutical industry is also giving a boost to the Indian economy. Not only that, but India is the largest manufacturer of generic drugs and exports them to different parts of the world. With this rapid growth rate, it is believed that India will soon be in the top 10 in global markets. Join a versatile third-party pharma manufacturing company to start your franchise company.

Quality Pharmaceutical Products List:-

DOYO has always dedicated itself to bringing better quality drugs. We deal in over 300+ drug formulations to cater to different markets and therapeutic segments of the pharmaceutical industry. We are constantly in touch with the growing demand of consumers. Known for our patient-centered approach, we have ensured that our partners will enjoy quality, sustainable, effective, reliable, and secure solutions. They approve DCGI with FSSAI certification. Our products include pharma tablets, capsules, soft gels, injectable, powders, sachets, etc. These include the following categories:

•        Anti-Alcoholism

•        Anti-Allergic

•        Anti-Arthritic

•        Antibiotics

•        Anticonvulsants

•        Antidepressants

•        Antidiabetics

•        Antiemetics & Vertigo

•        Anti-Inflammatory

•        Antimigraine

•        Antiparkinsonian

•        Antiplatelets

•        Antipsychotics

•        Antiulcer Hyperacidity

•        Anxiolytics

•        Cerebral Activators

•        Dermatological

•        NSAID’s

•        OTC Products

•        Supportive medication for COVID-19/Coronavirus

•        Vitamins & Minerals etc.

Associate with the Best Third-Party Manufacturer in India:-

DOYO is a leading pharma manufacturing company in India manufacturing quality products under GMP-WHO integrated manufacturing units. There are over 150+  affiliates who have joined us for our manufacturing facilities. We manufacture products on bulk orders that reduce production and labor costs. The features of a third party manufacturing company are

1. Advanced Equipment - We have GMP. Also, the manufacturing unit is high-tech and equipped with state-of-the-art technologies.

2. Functional Services - Third-party manufacturing companies are providing services such as on-time delivery, sales, and product marketing. Third-party services give you plenty of room to think about marketing with more ideas.

3. International Appreciation - A third-party manufacturing company manufactures products with a lot of time and space by working on every aspect of the manufacturing phase. Our manufactured products are receiving international and global praise all over the world.

4. Nurture your business with a low budget - Third-party manufacturing companies offer you the opportunity to grow your business venture on low investment. We make sure we create the best products for our customers so that they can grow further.

100% Quality Assurance at DOYO for Pharma Manufacturing:-

DOYO provides our customers with 100% quality assurance. Our company adheres to all international quality standards to meet the quality standards of manufactured products. We very examine about the quality of the product. Our manufacturing team works tirelessly to meet customer demand at any cost. We work to make our partner happy that he has invested his money in the right place. If you are also looking for a loyal and hardworking third-party manufacturing company in India then do is a better option.

- Strict products are displayed under strict screening criteria.

- The Quality Management Team closely monitors every step.

- H pH values, side effects, efficacy, freshness, and purity, etc. are all major elements of this screening.

Services Offered by the DOYO for Third-Party Manufacturing Company:-

DOYO is the third manufacturing company to offer its services across the country. Many pharma franchises are looking for third-party manufacturing services. We believe that it is the efforts of both companies that make the business successful.

We are providing our partner with many different categories and services

. We offer high-quality products in well-designed and packing materials.

We assure you of 100% best quality products from our end with incredible creations. Once disinfected, we deliver all stock to our customers and clients in complete safety. Our company assists in formulation trademark and drug registration.

Documents Required To Be Submitted for Pharma Manufacturing Services:-

 Our company is very professional when it comes to manufacturing services. Anyone wishing to join us for our services is required to submit the following  documents:

Details Signed and contracted construction agreement with full details

Non-identical certificate

Corporate office address

Company profile signed by direct directors or participants' documents (Aadhaar card and PAN card)

Copy the resolution to the authorized signatory deal

Drug license

Sales Tax

TIN or GST Registration Certificate

Logo and brand values

Ronal tonality and design (if)

 Important Information Related to Our Manufacturing Services:-

 DOYO is providing true and excellent third-party manufacturing services to companies around the world. We are providing exceptional services and some of the leading pharmaceutical companies like Dr. Reddy, Sun Pharma, Waters, Zeds Cadila, GAIA. Etc. We've listed some important information for those who want to join us:

Acceptable Batch Size / MOQ Q

Capsules - 1 million

Ry dry syrup - 20 million

ENT Medicine - 0.5 million

• Perfume - 1 lakh

OTC medicine - 1 lakh

Pharma

 injections - 0.5 million

Pharma tablets - 10 million tablets

• put • fear - 0.5 million

• Syrup - 10 lakhs

Note: Batch sizes may vary for beta formulas or complex formulas. For information, contact us!  Packaging Costing Atch Batch Expenses - (Quality Control, Consumer and Local Transportation Costs)

Price of pack packing material

Product

Raw material price

A fact construction costs.

Ur Securities  

Transit Insurance

Tax (GST applicable)

Process loss for RRM and PM etc

Expeditious and Secure Logistics Service in India For Third-Party Manufacturing:-

Well, we all know that coronavirus outbreaks have hit the industry hard. But we are associated with the best logistics service in India which is very responsible and serious about its duty. They are cleaning the products and then delivered them safely to your place without any delay. With the help of our logistics team, we are reaching out to our partners and customers across the country. Trust our services and products, we will not disappoint you.

[rohans18]

Antiemetics Market Analysis and Forecast to 2028

Global Antiemetics Market, By Drug Class (5-HT3 Receptor Antagonists, Dopamine Antagonists, NK1 Receptor Antagonist, Antihistamines (H1 histamine receptor antagonists), Cannabinoids, Benzodiazepines, Anticholinergics, Steroids, Others), Application (Chemotherapy, Motion Sickness, Gastroenteritis, General Anesthetics, Opioid Analgesics, Dizziness, Pregnancy, Food Poisoning, Emotional Stress, Other), End-User (Hospitals, Clinics, Pharmacies, Online Pharmacies), Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028

An expert team performs systematic, object-oriented and complete market research study to provide the facts associated with any subject in the field of marketing via Antiemetics marketing report. The report has a lot to offer to both established and new players in the Antiemetics industry with which they can completely understand the market. SWOT analysis and Porter’s Five Forces analysis methods are used wherever applicable, while generating this report. One of the most important parts of an international Antiemetics market report is competitor analysis with which businesses can estimate or analyse the strengths and weaknesses of the competitors.

Key Players

The major players covered in the antiemetics market report are GlaxoSmithKline plc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., Mylan N.V., Eli Lilly and Company, Johnson & Johnson Services, Inc, Baxter., Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche Ltd, Ipca Laboratories Ltd, Eisai Co., Ltd, Abbott, Sanofi, Novartis AG, Kyowa Kirin Co., Ltd., Heron Therapeutics, Inc. and Aurobindo Pharma among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

 Browse More Info @ https://www.databridgemarketresearch.com/reports/global-antiemetics-market

With the help of credible Antiemetics market analysis report, businesses can make out the reaction of the consumers to an already existing product in the market. The report includes estimations of recent state of the market, CAGR values, market size and market share, revenue generation, and necessary changes required in the future products. A wide-ranging competitor analysis helps build superior strategies of production, improvement in certain product, its advertising or marketing and promotion for the business. Exhaustive and comprehensive market study performed in the wide ranging Antiemetics market report offers current and forthcoming opportunities that put light on the future market investment.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Antiemetics Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:  Global Market

Part 04: Global Market Size

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 More Reports:

Diuretic Drugs Market

Patient Engagement Technology Market

Healthcare Business Intelligence Market

Chinese Hamster Ovary cells (CHO) Market

Anti-cancer Drug Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: sales@databridgemarketresearch.com

[pranalipawarshinde]

Ongoing trends of the Post-operative Nausea and Vomiting (PONV) Market 2018-2026

Growth of the Post-operative Nausea and Vomiting (PONV) Market:Overview

Transparency Market Research (TMR) has published a new report titled, “Post-operative Nausea and Vomiting (PONV) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”, in June 2018. According to the report, the global post-operative nausea and vomiting (PONV) market was valued at US$ 1,608.6 Mn in 2017 and is projected to expand at a CAGR of 8% from 2018 to 2026. Increase in patient population experiencing post-operative nausea and vomiting, rise in adoption rate of combination therapies as well as non-pharmacological treatment modes, surge in funding, and launch of newer therapies are expected to boost the growth of the post-operative nausea and vomiting (PONV) during the forecast period from 2018 to 2026. North America and Europe are projected to dominate the global PONV market in the near future, primarily due to rise in patient population, steps taken by governments to support the development of novel therapies, and extensive research undertaken for the development of low cost drugs in these regions.

Request A Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2969

The global PONV market in Asia Pacific is anticipated to expand at a high CAGR from 2018 to 2026. This can be ascribed to large patient population, rise in chronic diseases requiring surgical intervention in countries such as China and Japan, and various initiatives undertaken by the government and non-profit organizations to promote awareness about the treatment of post-operative complications. The PONV market in Asia Pacific is expected to expand at a CAGR of 8.5% during the forecast period.

High Incidence Rate and Significant Demand for Combination Therapy to Drive Market

Post-operative nausea & vomiting is one of the most common complications after general anesthesia, occurring in up to 80% patients. Despite impressive advances in the field of anesthesia, 25% to 30% of patients continue to experience PONV. Multiple factors, including the anesthetic agent delivered, are associated with the increased incidence of PONV. A study published by the National Center for Biotechnology Information stated that the incidence of PONV has been reported in 20% to 40% patients with postoperative opioids. However, the incidence rate can increase to nearly 80% in patients with multiple risk factors for PONV, if antiemetic prophylaxis is not appropriate.

Demand for combination drugs is rising among different classes, with various mechanism of actions for use in patients with moderate to high risk for PONV. Large number of clinical practice organizations also advocate usage of prophylactic antiemetic combinations. PONV is caused by multiple factors, and therefore, demand for combination antiemetic therapy among patients is high. None of the available medicines is single-handedly effective in preventing PONV, more so in high-risk patients. This is because majority of these medicines act through blockade of one receptor. Hence, better prophylaxis can be achieved using a combination therapy owing to the multi-modal etiology of PONV.

Request Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2969

Serotonin Antagonists to be an Attractive Product Segment

The report offers detailed segmentation of the global PONV market based on treatment type and distribution channel. In terms of treatment type, the serotonin antagonists segment is poised to expand at the highest CAGR during the forecast period from 2018 to 2026. Serotonin antagonists have a proven safety profile and are effective in the management of post-operative nausea and vomiting. Serotonin antagonists such as dolasetron, ondansetron, tropisetron, and granisetron competitively and selectively bind to 5-HT (3) receptors, thereby blocking serotonin binding in the regions of CNS involved in emesis.

Non-pharmacological Treatment Segment to Record High CAGR

The non-pharmacological treatment segment is projected to dominate the global PONV market during the forecast period. The segment is anticipated to expand at a CAGR of 12% from 2018 to 2026. Significant rise in demand for non-pharmacological treatment methods has led to increase in usage of these methods. Surge in usage of non-pharmacologic treatment methods such as acupuncture, transcutaneous nerve stimulation, aromatherapy, and acupoint stimulation is likely to boost the growth of the segment during the forecast period.

Asia Pacific to Present Significant Opportunities

In terms of revenue, the PONV market in Asia Pacific is expected to expand at a high CAGR during the forecast period from 2018 to 2026. The region is projected to gain market share by 2026. Asia Pacific’s dominance of the global market can be attributed to rise in the number of patients undergoing surgical procedures and increase in compliance to pharmacologic and non-pharmacologic treatments. Presence of local pharmaceutical companies with massive manufacturing units in the countries of this region is expected to propel the market of this region.

Request for covid19 Impact Analysis: https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=2969

M&A and New Product Development are Key Trends among Leading Players

The report also provides profiles of the leading players operating in the global PONV market. Acacia Pharma, F. Hoffmann-La Roche AG, Novartis AG, Ani Pharmaceuticals, Inc., Camurus AB, Sanofi, Helsinn Holding S.A., Eisai Corporation, Merck & Co., and GlaxoSmithKline Corporation are the prominent players in the market having proprietary products and technologies. The major growth strategy adopted by these companies is new product development.

More Trending Reports by Transparency Market Research:

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com